Targeted drug shows promise for rare genetic cancers
Disease control
Completed
This study tested an experimental drug called ENV-101 (Taladegib) in 20 people with advanced solid tumors that have a specific genetic change (PTCH1 mutation). The goal was to see if the drug could shrink tumors and to check for side effects. Participants had cancers that did not…
Phase: PHASE2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC